Frontlight ResearchEarly access
Taking peoplePhase 3
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
Key facts
- Who runs it
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 328 people, planned
- Started
- 11 Nov 2024
- Planned end
- 30 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- GP681 40mg
- GP681 Simulant
- Record updated
- 4 December 2024
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Male or female patients aged ≥12 years at the time of signing the informed consent form
- Patients with a diagnosis of influenza confirmed by all of the following:; Positive throat or nose swab by rapid influenza antigen test (RAT) (where rapid influenza virus nucleic acid test or other rapid molecular diagnostic methods are also acceptable); Fever (axillary temperature ≥37.3℃) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken; At least one of the following systemic symptoms and respiratory symptoms respectively associated with influenza are present with a severity of moderate or greater:; Systemic symptoms: headache, fever or chills, muscle or joint aches, fatigue; Respiratory system symptoms: cough, sore throat, nasal congestion
- The time interval between the onset of symptoms and random enrollment is 48 hours or less. The onset of symptoms is defined as either:; Time of the first increase in body temperature (axillary temperature ≥37.3℃); Time when the patient experiences at least 1 new general or respiratory symptom related to influenza
- Referring to the standards of the Centers for Disease Control and Prevention (CDC) in the United States and the definition of high-risk populations for influenza complications in the "Expert Consensus on Diagnosis and Treatment of Influenza in Adults in the Emergency Department (2022 Edition)", that is, if at least one of the following criteria is met, the patient will be considered at high risk of influenza complications:; Asthma or chronic lung diseases [such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, chronic bronchitis, bronchiectasis, emphysema, chronic interstitial pneumonia, etc.]; Endocrine disorders (including diabetes); Residents of long-term care institutions (such as nursing homes); Immune system impairment (including patients receiving chronic systemic corticosteroid treatment of ≤20mg/d prednisone or an equivalent dose); Neurological and neurodevelopmental disorders (including brain, spinal cord, peripheral nerve and muscle diseases, such as cerebral palsy, epilepsy (episodic disorders), stroke, muscular dystrophy or spinal cord injury); Heart diseases (such as congenital heart disease, congestive heart failure, or coronary artery disease), but not including hypertension without any other cardiac-related symptoms; Patients aged ≥65 years; Blood system diseases (such as sickle cell disease); Metabolic system diseases (such as hereditary metabolic diseases and mitochondrial diseases); Liver diseases (such as chronic hepatitis B, chronic hepatitis C, non-alcoholic steatohepatitis); Kidney diseases (estimated glomerular filtration rate eGFR ≥ 30 mL/min/1.73m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula); Obese patients (BMI ≥ 30 kg/m2); Female patients within 2 weeks postpartum and not breastfeeding
- Subjects of child-bearing potential who agree to use a highly effective method of contraception for 1 month after drug withdrawal
- Subjects and/or their guardian who are willing to provide written informed consent and consent to participate in the study, able to understand the study and comply with all study procedures, including patient health diary records
Who cannot take part
- Cancer patients who are currently receiving or have received chemotherapy or radiation therapy within the past year (excluding non-melanoma skin cancer and thyroid cancer)
- Organ or bone marrow transplant recipients
- Patients who are currently receiving >20mg/d of prednisone or equivalent chronic systemic corticosteroid therapy
- Patients who have used anti-influenza virus drugs (including neuraminidase inhibitors, hemagglutinin inhibitors, and M2 ion channel blockers, such as oseltamivir, zanamivir, palivizumab, favipiravir, abidol, marabolexavir, amantadine or rimantadine or other anti-influenza virus drugs approved by NMPA) within the past 2 weeks or who have received influenza vaccination within the past 6 months
- Exclusion of participants who have received clinical research or screening within the past 30 days for any indication with a trial drug or device, or who have received clinical research for a monoclonal antibody drug for viral diseases within the past year
- Known to have had a previous history of severe liver function impairment such as cirrhosis with ascites, hepatic encephalopathy, or a history of upper gastrointestinal bleeding
- History of allergic reactions attributed to GP681,Acetaminophen, bromohexine hydrochloride or any of the ingredients of its formulation
- Known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to chronic diarrhea, inflammatory bowel disease, tuberculosis of the intestines, gastrinoma, short bowel syndrome, postoperative gastrectomy, etc.)
- Screening patients who, in the opinion of the investigator, require hospitalization due to severe influenza virus infection
- Screening patients who, at the time of screening, are clinically diagnosed with bacterial or other viral infections requiring systemic antibacterial or antiviral treatment
- Known HIV-infected patients
- Individuals with a history of alcohol abuse or substance abuse (more than 14 units of alcohol per week, 1 unit of alcohol = 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine with an alcohol content of 12%)
- Estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula <30mL/min/1.73m2 at the time of screening
- Adult reproductive-age females who are pregnant or breastfeeding or who have a positive pregnancy test. Women who are infertile (i.e., women who have had a hysterectomy, bilateral oophorectomy, or tubal ligation for medical reasons or who are postmenopausal - defined as age > 50 years and menopause has occurred for at least 2 years) do not need a pregnancy test
- Patients who, in the opinion of the Investigator, may not be qualified or suitable for the study
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.
The 2 groups in the trial
- GP681 tablet 40mgTreatment being tested
Patients in the GP681 tablet 40mg group will receive a single oral dose of GP681 tablet 40mg.
Treatment: GP681 40mg
- Placebo groupPlacebo, for comparison
Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg.
Treatment: GP681 Simulant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in Patients With Influenza at High Risk of Influenza Complications
- Record updated
- 4 December 2024